Evidence map›Paper›PMID 40162972›Full record

ArticleBlood cancer discovery2025

Enhancer Hijacking Discovery in Acute Myeloid Leukemia by Pyjacker Identifies MNX1 Activation via Deletion 7q.

Etienne Sollier, Anna Riedel, Umut H Toprak, Justyna A Wierzbinska, Dieter Weichenhan, Jan Philipp Schmid, Mariam Hakobyan, Aurore Touzart, Ekaterina Jahn, Binje Vick and 47 more

Abstract read
In one paragraph

Article in Blood cancer discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

57 authors.

Etienne Sollier *Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-3612-8562
Anna Riedel *Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-0626-3894
Umut H Toprak *Division of Neuroblastoma Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0009-0009-6923-6816
Justyna A WierzbinskaDivision of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0009-0002-9747-2938
Dieter WeichenhanDivision of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-7915-412X
Jan Philipp SchmidResearch Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Munich, German Research Center for Environmental Health, Munich, Germany.ORCID 0009-0001-3869-8868
Mariam HakobyanSection of Translational Cancer Epigenomics, Division of Translational Medical Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0003-4719-5186
Aurore TouzartDivision of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-8888-2292
Ekaterina JahnDepartment of Internal Medicine III, University Hospital Ulm, Ulm, Germany.ORCID 0009-0001-0741-1166
Binje VickResearch Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Munich, German Research Center for Environmental Health, Munich, Germany.ORCID 0000-0003-1956-2778
Fiona Brown-BurkeDivision of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0001-6692-8678
Katherine KellyDivision of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0009-0003-6043-4927
Simge KelekçiDivision of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-4896-0110
Anastasija PejkovskaDivision of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-8727-544X
Ashish GoyalDivision of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-9830-3987
Marion BährDivision of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0009-0001-3812-8865
Kersten BreuerDivision of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0003-3716-7739
Mei-Ju May ChenDivision of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-8721-0304
Maria Llamazares-PradaDivision of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0001-6559-9374
Mark HartmannSection of Translational Cancer Epigenomics, Division of Translational Medical Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-4072-4658
Maximilian SchönungSection of Translational Cancer Epigenomics, Division of Translational Medical Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-9778-9698
Nadia CorreiaHeidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.ORCID 0000-0003-1823-5564
Andreas TrumppHeidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.ORCID 0000-0002-6212-3466
Yomn AbdullahDivision Systems Biology of Signal Transduction, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-5694-0910
Ursula KlingmüllerDivision Systems Biology of Signal Transduction, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0001-9845-3099
Sadaf S MughalDivision Applied Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0003-3468-8467
Benedikt BrorsNational Center for Tumor Diseases (NCT), NCT Heidelberg, A partnership between DKFZ and Heidelberg University Hospital, Heidelberg, Germany.ORCID 0000-0001-5940-3101
Frank WestermannDivision of Neuroblastoma Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0003-1584-3636
Elias UlrichGerman Cancer Consortium (DKTK), Heidelberg, Germany.ORCID 0000-0003-2489-7265
Robert J AutryGerman Cancer Consortium (DKTK), Heidelberg, Germany.ORCID 0000-0002-6965-2942
Matthias SchlesnerBiomedical Informatics, Data Mining and Data Analytics, University of Augsburg, Augsburg, Germany.ORCID 0000-0002-5896-4086
Sebastian VosbergGerman Cancer Consortium (DKTK), Partner site Munich, A partnership between DKFZ and University Hospital LMU Munich, Munich, Germany.ORCID 0000-0002-8464-1483
Tobias HeroldGerman Cancer Consortium (DKTK), Partner site Munich, A partnership between DKFZ and University Hospital LMU Munich, Munich, Germany.ORCID 0000-0002-9615-9432
Philipp A GreifGerman Cancer Consortium (DKTK), Partner site Munich, A partnership between DKFZ and University Hospital LMU Munich, Munich, Germany.ORCID 0000-0002-3744-7936
Dietmar PfeiferDepartment of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, Germany.ORCID 0000-0003-2684-5944
Michael LübbertDepartment of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, Germany.ORCID 0000-0003-1186-1650
Thomas FischerDepartment of Hematology and Oncology, Medical Center, Otto-von-Guericke University, Magdeburg, Germany.ORCID 0000-0001-5071-3808
Florian H HeidelHematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School (MHH), Hannover, Germany.ORCID 0000-0003-2438-1955
Claudia GebhardInterventional Immunology, Leibniz Institute for Immunotherapy, Regensburg, Germany.ORCID 0000-0002-5459-8381
Wencke WalterMLL Munich Leukemia Laboratory, Munich, Germany.ORCID 0000-0002-5083-9838
Torsten HaferlachMLL Munich Leukemia Laboratory, Munich, Germany.ORCID 0000-0003-0196-2837
Ann-Kathrin EisfeldClara D. Bloomfield Center for Leukemia Outcomes Research, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.ORCID 0000-0001-6442-1419
Krzysztof MrózekClara D. Bloomfield Center for Leukemia Outcomes Research, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.ORCID 0000-0002-1408-5063
Deedra NicoletClara D. Bloomfield Center for Leukemia Outcomes Research, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.ORCID 0000-0001-7796-0251
Lars BullingerDepartment of Hematology, Oncology, and Cancer Immunology, Charité, Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0002-5890-5510
Leonie SmeenkDepartment of Hematology, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0001-7025-8515
Claudia Erpelinck-VerschuerenDepartment of Hematology, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0002-3965-4488
Roger Mulet-LazaroDepartment of Hematology, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0003-0298-7948
Ruud DelwelDepartment of Hematology, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0001-6903-3271
Aurélie ErnstGerman Cancer Consortium (DKTK), Heidelberg, Germany.ORCID 0000-0002-8082-3677
Michael SchererDivision of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0001-7990-6179
Pavlo LutsikDivision of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0001-9383-8555
Irmela JeremiasResearch Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Munich, German Research Center for Environmental Health, Munich, Germany.ORCID 0000-0003-1773-7677
Konstanze DöhnerDepartment of Internal Medicine III, University Hospital Ulm, Ulm, Germany.ORCID 0000-0002-2261-9862
Hartmut DöhnerDepartment of Internal Medicine III, University Hospital Ulm, Ulm, Germany.ORCID 0000-0003-2116-5536
Daniel B Lipka *Section of Translational Cancer Epigenomics, Division of Translational Medical Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0001-5081-7869
Christoph Plass *Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0003-2554-3952

Funding

Towards an inclusive genomic risk classification for acute myeloid leukemia (AML)R01CA284595 · NCI · OHIO STATE UNIVERSITY · PI Ann-Kathrin Eisfeld, H. LEIGHTON GRIMES · 2023 to 2026
$2.6M
Understanding Treatment Response Patterns And Therapy Resistance In IDH-Mutant AMLR01CA262496 · NCI · OHIO STATE UNIVERSITY · PI Ann-Kathrin Eisfeld, Elaine R. Mardis · 2022 to 2026
$2.6M
The role of inflammation in the regulation of immune response in acute myeloid leukemiaR01CA283574 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Iannis Aifantis, Ann-Kathrin Eisfeld · 2023 to 2026
$2.3M
American Cancer Society (ACS) R01CA262496American Cancer Society (ACS) R01CA283574-01American Cancer Society (ACS) R01CA284595-01Deutsche Forschungsgemeinschaft (DFG) FOR 2674Deutsche Forschungsgemeinschaft (DFG) HE6233/10-1Deutsche Forschungsgemeinschaft (DFG) HE6233/4-2Deutsche Forschungsgemeinschaft (DFG) HE6233/9-1Deutsche Forschungsgemeinschaft (DFG) SFB 1074Deutsche Forschungsgemeinschaft (DFG) SPP1463National Center for Tumor Diseases (NCT) HIPO-030NCI NIH HHS R01 CA262496NCI NIH HHS R01 CA283574NCI NIH HHS R01 CA284595
6 · The paper itself

Abstract

Acute myeloid leukemia (AML) with complex karyotype is characterized by high genomic complexity, including frequent TP53 mutations and chromothripsis. Genomic rearrangements can reposition active enhancers near proto-oncogenes, leading to their aberrant expression; however, a comprehensive understanding of these events in AML is still incomplete. To facilitate the discovery of such "enhancer hijacking" events, we developed Pyjacker, a computational tool, and applied it to 39 AML samples with complex karyotype. Pyjacker identified several enhancer hijacking events in AML patient samples, including aberrant expression of MNX1, which can result from del(7)(q22q36) and is associated with hijacking of a CDK6 enhancer. MNX1 activation occurred in 1.4% of patients with AML and showed significant co-occurrence with BCOR mutations. Through a xenograft mouse model, we demonstrated that MNX1 is required for leukemia cell fitness. Pyjacker is an easy-to-use, accurate, and broadly applicable tool for identifying consequences of genomic events driving tumorigenesis, especially when germline genomic data are missing. SIGNIFICANCE: This study examines the consequences of structural alterations in AML and demonstrates that proto-oncogene activation by enhancer hijacking is an understudied pathomechanism. MNX1 overexpression demonstrates that deletions on chromosome 7q can not only lead to haploinsufficiency but also to activation of oncogenes by enhancer hijacking.

Indexed as

Chromosome DeletionChromosomes, Human, Pair 7Enhancer Elements, GeneticHomeodomain ProteinsLeukemia, Myeloid, AcuteTranscription FactorsAnimalsHumansMiceProto-Oncogene MasHomeodomain ProteinsMAS1 protein, humanMNX1 protein, humanProto-Oncogene MasTranscription Factors

Identifiers

PMID40162972
PMCPMC12209774

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.